Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 inact mut |
Therapy | Adavosertib + Radiotherapy |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 inact mut | breast cancer | sensitive | Adavosertib + Radiotherapy | Preclinical | Actionable | In a preclinical study, Adavosertib (MK-1775) increased the efficacy of radiation in breast cancer cells with defective TP53 in culture (PMID: 21799033). | 21799033 |
PubMed Id | Reference Title | Details |
---|---|---|
(21799033) | MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. | Full reference... |